| Entry |
|
|---|
| Name |
Prasugrel hydrochloride (JAN/USAN);
Effient (TN)
|
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C20H20FNO3S. HCl
|
|---|
| Exact mass |
409.0915
|
|---|
| Mol weight |
409.902
|
|---|
| Structure |
   |
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 3399 |
|
|---|
| Efficacy |
Platelet aggregation inhibitor, Purinergic receptor P2Y12 antagonist |
|---|
| Disease |
Unstable angina [DS: H01632] Myocardial infarction [DS: H01730] |
|---|
| Comment |
Thienopyridine derivative
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
|
|---|
| Interaction |
CYP inhibition: CYP2B6 [HSA: 1555]
 |
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AC Platelet aggregation inhibitors excl. heparin
B01AC22 Prasugrel
D05597 Prasugrel hydrochloride (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Blood Products/Modifiers/Volume Expanders
Platelet Modifying Agents
Prasugrel
D05597 Prasugrel hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
339 Miscellaneous
3399 Others
D05597 Prasugrel hydrochloride (JAN/USAN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Purine / pyrimidine
P2RY12
D05597 Prasugrel hydrochloride (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05597
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05597
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05597
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05597
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D05597
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 27
1 N1y N 17.0100 -15.7500
2 C1x C 17.0100 -14.3500
3 C1x C 18.2000 -13.6500
4 C8y C 19.4600 -14.3500
5 C8y C 19.4600 -15.7500
6 C1x C 18.2000 -16.4500
7 S2x S 20.7900 -13.9300
8 C8y C 21.5600 -15.0500
9 C8x C 20.7900 -16.1700
10 O7a O 22.9600 -15.0500
11 C7a C 23.6600 -13.8600
12 C1a C 25.0600 -13.8600
13 O6a O 22.9600 -12.6700
14 C1c C 15.8200 -16.4500
15 C8y C 14.6300 -15.7500
16 C5a C 15.8200 -17.8500
17 O5a O 17.0100 -18.5500
18 C1y C 14.6300 -18.5500
19 C8y C 14.6300 -14.3500
20 C8x C 13.3700 -13.6500
21 C8x C 12.1800 -14.3500
22 C8x C 12.1800 -15.7500
23 C8x C 13.3700 -16.4500
24 C1x C 13.2300 -18.5500
25 C1x C 13.9300 -19.7400
26 X F 15.8200 -13.6500
27 X Cl 24.7800 -18.0600
BOND 29
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 2
5 5 6 1
6 1 6 1
7 4 7 1
8 7 8 1
9 8 9 2
10 5 9 1
11 8 10 1
12 10 11 1
13 11 12 1
14 11 13 2
15 1 14 1
16 14 15 1
17 14 16 1
18 16 17 2
19 16 18 1
20 15 19 2
21 19 20 1
22 20 21 2
23 21 22 1
24 22 23 2
25 15 23 1
26 18 24 1
27 24 25 1
28 25 18 1
29 19 26 1
|
|---|
